{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:35:58Z","timestamp":1747204558017,"version":"3.40.5"},"posted":{"date-parts":[[2023,3,21]]},"group-title":"In Review","reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,3,14]]},"abstract":"<title>Abstract<\/title><p>Haploidentical donors offer a potentially readily available donor, especially for non-White patients, for blood or marrow transplantation (BMT). In this collaboration across North America, we retrospectively analyzed outcomes of first BMT using haploidentical donor and posttransplantation cyclophosphamide (PTCy) in MDS\/MPN-overlap neoplasms (MDS\/MPN), an otherwise incurable hematological neoplasm. We included 120 patients, 38% of non-White\/Caucasian ethnicity, across 15 centers with median age at BMT 62.5 years. The median follow-up is 2.4 years. Graft failure was reported in 6% patients. At 3-years, nonrelapse mortality (NRM) was 25%, relapse 27%, grade 3-4 acute graft versus host disease (GVHD) 12%, chronic GVHD requiring systemic immunosuppression 14%, progression-free survival (PFS) 48% and overall survival (OS) 56%. On multivariable analysis, statistically significant associations included older age at BMT (per decade increment) with NRM (sdHR 3.28, 95%CI 1.30-8.25), PFS (HR 1.98, 95% 1.13-3.45) and OS (HR 2.01, 95% CI 1.11-3.63), presence of mutation in EZH2\/RUNX1\/SETBP1 with relapse (sdHR 2.61, 95%CI 1.06-6.44), and splenomegaly at BMT\/prior splenectomy with OS (HR 2.20, 95%CI 1.04-4.65). Haploidentical donors are a viable option for BMT in MDS\/MPN, especially for those disproportionately represented in the unrelated donor registry. Disease-related factors including splenomegaly and high-risk mutations dominate outcomes following BMT.<\/p>","DOI":"10.21203\/rs.3.rs-2691216\/v1","type":"posted-content","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T16:32:43Z","timestamp":1679416363000},"source":"Crossref","is-referenced-by-count":2,"title":["Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic\/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"first","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4636","authenticated-orcid":false,"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros","family":"Karantanos","sequence":"additional","affiliation":[{"name":"TKARANT1@JHMI.EDU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Wall","sequence":"additional","affiliation":[{"name":"The Ohio State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1551-3496","authenticated-orcid":false,"given":"Lukasz","family":"Gondek","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[{"name":"Northside Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alla","family":"Keyzner","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-0850","authenticated-orcid":false,"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-9875","authenticated-orcid":false,"given":"Michael","family":"Grunwald","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute, Atrium Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameem","family":"Abedin","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalyan","family":"Nadiminti","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine and Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron","family":"Gerds","sequence":"additional","affiliation":[{"name":"Cleveland Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-6781","authenticated-orcid":false,"given":"Shannon","family":"McCurdy","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr Al","family":"Malki","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-7292","authenticated-orcid":false,"given":"Haris","family":"Ali","sequence":"additional","affiliation":[{"name":"City of Hope"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard John","family":"Jones","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman","family":"Otoukesh","sequence":"additional","affiliation":[{"name":"City of Hope"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data","author":"Arber DA","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes J, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey E, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Goekbuget N, Gotlib JR, Hellstrom-Lindberg E, Hobbs G, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Lowenberg B, Macintyre EA, Malcovati L, Mullighan CG, Niemeyer CM, Odenike O, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer C, Schmitt-Graeff A, Shimamura A, Sierra J, Stock W, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Dohner H, Tefferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. Blood. 2022.","journal-title":"Blood"},{"year":"2022","author":"Khoury JD","key":"ref2","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.leukres.2018.11.003","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan","volume":"75","author":"Itonaga H","year":"2018","unstructured":"Itonaga H, Ota S, Ikeda T, Taji H, Amano I, Hasegawa Y, Ichinohe T, Fukuda T, Atsuta Y, Tanizawa A, Kondo T, Miyazaki Y. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. Leuk Res. 2018;75:50\u201357.","journal-title":"Leuk Res"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park S","year":"2013","unstructured":"Park S, Labopin M, Yakoub-Agha I, Delaunay J, Dhedin N, Deconinck E, Michallet M, Robin M, De Revel T, Bernard M, Vey N, Lioure B, Lapusan S, Tabrizi R, Bourhis JH, Huynh A, Beguin Y, Socie G, Dreyfus F, Fenaux P, Mohty M. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol. 2013;90(5):355\u2013364.","journal-title":"Eur J Haematol"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood.2021015173","article-title":"Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis","volume":"140","author":"Robin M","year":"2022","unstructured":"Robin M, de Wreede LC, Padron E, Bakunina K, Fenaux P, Koster L, Nazha A, Beelen DW, Rampal RK, Sockel K, Komrokji RS, Gagelmann N, Eikema DJ, Radujkovic A, Finke J, Potter V, Killick SB, Legrand F, Solary E, Broom A, Garcia-Manero G, Rizzoli V, Hayden P, Patnaik MM, Onida F, Yakoub-Agha I, Itzykson R. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022;140(12):1408\u20131418.","journal-title":"Blood"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/10428194.2016.1217529","article-title":"Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome\/myeloproliferative neoplasm (MDS\/MPN) overlap syndromes","volume":"58","author":"Sharma P","year":"2017","unstructured":"Sharma P, Shinde SS, Damlaj M, Hefazi Rorghabeh M, Hashmi SK, Litzow MR, Hogan WJ, Gangat N, Elliott MA, Al-Kali A, Tefferi A, Patnaik MM. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome\/myeloproliferative neoplasm (MDS\/MPN) overlap syndromes. Leuk Lymphoma. 2017;58(4):872\u2013881.","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"ref7","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","article-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","volume":"6","author":"Ambinder A","year":"2022","unstructured":"Ambinder A, Jain T, Tsai HL, Horowitz MM, Jones RJ, Varadhan R. HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Adv. 2022;6(14):4335\u20134346.","journal-title":"Blood Adv"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte S","year":"2022","unstructured":"Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, Iqbal M, Grunwald MR, Dholaria B, Elmariah H, Ozga M, Singh A, Abedin S, DeZern AE, Jones RJ, Gupta V, Gerds AT, Jain T. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022;36(3):856\u2013864.","journal-title":"Leukemia"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik L","year":"2008","unstructured":"Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641\u2013650.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"ref10","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1182\/bloodadvances.2020002945","article-title":"Allogeneic transplantation for Ph + acute lymphoblastic leukemia with posttransplantation cyclophosphamide","volume":"4","author":"Webster JA","year":"2020","unstructured":"Webster JA, Luznik L, Tsai HL, Imus PH, DeZern AE, Pratz KW, Levis MJ, Gojo I, Showel MM, Prince G, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Jain T, Fuchs EJ, Gladstone DE, Gocke CB, Ali SA, Huff CA, Borrello IM, Swinnen L, Wagner-Johnston N, Ambinder RF, Jones RJ, Smith BD. Allogeneic transplantation for Ph + acute lymphoblastic leukemia with posttransplantation cyclophosphamide. Blood Adv. 2020;4(20):5078\u20135088.","journal-title":"Blood Adv"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1080\/10428194.2022.2057488","article-title":"Genomic landscape of myelodysplastic\/myeloproliferative neoplasm can predict response to hypomethylating agent therapy","volume":"63","author":"Karantanos T","year":"2022","unstructured":"Karantanos T, Tsai HL, Gondek LP, DeZern AE, Ghiaur G, Dalton WB, Gojo I, Prince GT, Webster J, Ambinder A, Smith BD, Levis MJ, Varadhan R, Jones RJ, Jain T. Genomic landscape of myelodysplastic\/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leuk Lymphoma. 2022;63(8):1942\u20131948.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2021.280203","article-title":"The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis","volume":"108","author":"Mei M","year":"2023","unstructured":"Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023;108(1):150\u2013160.","journal-title":"Haematologica"},{"issue":"16","key":"ref13","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo L","year":"2020","unstructured":"Palomo L, Meggendorfer M, Hutter S, Twardziok S, Adema V, Fuhrmann I, Fuster-Tormo F, Xicoy B, Zamora L, Acha P, Kerr CM, Kern W, Maciejewski JP, Sole F, Haferlach C, Haferlach T. Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms. Blood. 2020;136(16):1851\u20131862.","journal-title":"Blood"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjh.17534","article-title":"Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes","volume":"193","author":"Karantanos T","year":"2021","unstructured":"Karantanos T, Gondek LP, Varadhan R, Moliterno AR, DeZern AE, Jones RJ, Jain T. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes. Br J Haematol. 2021;193(6):1142\u20131150.","journal-title":"Br J Haematol"},{"issue":"20","key":"ref15","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u20132405.","journal-title":"Blood"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena C","year":"2016","unstructured":"Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E, Ambaglio I, Lopez-Pavia M, Zibellini S, Kuendgen A, Travaglino E, Sancho-Tello R, Catricala S, Vicente AI, Haferlach T, Haferlach C, Sanz GF, Malcovati L, Cazzola M. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u20131417.","journal-title":"Blood"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg PL","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u20132465.","journal-title":"Blood"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona MR","year":"2015","unstructured":"Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF, Group MMIW. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood. 2015;125(12):1857\u20131865.","journal-title":"Blood"},{"issue":"8","key":"ref19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy","volume":"27","author":"Kharfan-Dabaja MA","year":"2021","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27(8):642\u2013649.","journal-title":"Transplant Cell Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/9781118416426.ch77","article-title":"Mechanisms and Treatment of Graft Failure","author":"Lowsky R","year":"2015","unstructured":"Lowsky R, Messner H. Mechanisms and Treatment of Graft Failure. Thomas\u2019 Hematopoietic Cell Transplantation; 2015:944\u2013958.","journal-title":"Thomas\u2019 Hematopoietic Cell Transplantation"},{"year":"1995","author":"Przepiorka D","key":"ref21","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825\u2013828."},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade","volume":"97","author":"Rowlings PA","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socie G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855\u2013864.","journal-title":"Br J Haematol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-017-0045-4","article-title":"EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental","volume":"8","author":"Patnaik MM","year":"2018","unstructured":"Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling R, Hanson C, Gangat N, Tefferi A. EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer J. 2018;8(1):12.","journal-title":"Blood Cancer J"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2014-04-567057","article-title":"Genetic alterations of the cohesin complex genes in myeloid malignancies","volume":"124","author":"Thota S","year":"2014","unstructured":"Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, Sekeres MA, Levine RL, Maciejewski JP. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood. 2014;124(11):1790\u20131798.","journal-title":"Blood"},{"issue":"15","key":"ref25","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1158\/1078-0432.CCR-14-2203","article-title":"Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes","volume":"21","author":"Tsai SC","year":"2015","unstructured":"Tsai SC, Shih LY, Liang ST, Huang YJ, Kuo MC, Huang CF, Shih YS, Lin TH, Chiu MC, Liang DC. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes. Clin Cancer Res. 2015;21(15):3541\u20133551.","journal-title":"Clin Cancer Res"},{"key":"ref26","first-page":"1141","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray RJ","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics. 1988;16:1141\u20131154.","journal-title":"Annals of Statistics"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox DR","year":"1972","unstructured":"Cox DR. Regression models and life tables (with discussion). J R Statist Soc B. 1972;34:187\u2013220.","journal-title":"J R Statist Soc B"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine JP","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JASA. 1999;94:496\u2013509.","journal-title":"JASA"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison DE","year":"2008","unstructured":"Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45\u201352.","journal-title":"Blood"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.bbmt.2020.05.013","article-title":"Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic\/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation","volume":"26","author":"Kurosawa S","year":"2020","unstructured":"Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Murata M, Aoki J. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic\/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020;26(9):1607\u20131611.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis","volume":"28","author":"Jain T","year":"2022","unstructured":"Jain T, Tsai HL, DeZern AE, Gondek LP, Elmariah H, Bolanos-Meade J, Luznik L, Fuchs E, Ambinder R, Gladstone DE, Imus P, Webster J, Prince G, Ghiaur G, Smith BD, Ali SA, Ambinder A, Dalton WB, Gocke CB, Huff CA, Gojo I, Swinnen L, Wagner-Johnston N, Borrello I, Varadhan R, Levis M, Jones RJ. Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. Transplant Cell Ther. 2022;28(5):259 e251-259 e211.","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"ref32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison C","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u2013798.","journal-title":"N Engl J Med"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"e317-e324","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison CN","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317-e324.","journal-title":"Lancet Haematol"},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Jr., Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"15","key":"ref35","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"Myelodysplastic Syndrome Clinical Research C. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)","volume":"22","author":"Padron E","year":"2016","unstructured":"Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS, Myelodysplastic Syndrome Clinical Research C. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res. 2016;22(15):3746\u20133754.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"ref36","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron E","year":"2013","unstructured":"Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013;121(25):5068\u20135077.","journal-title":"Blood"},{"key":"ref37","first-page":"1","article-title":"Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease","author":"Sanber K","year":"2023","unstructured":"Sanber K, Ye K, Tsai HL, Newman M, Webster JA, Gojo I, Ghiaur G, Prince GT, Gondek LP, Smith BD, Levis MJ, DeZern AE, Ambinder AJ, Dalton WB, Jain T. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. Leuk Lymphoma. 2023:1\u201310.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bbmt.2018.11.016","article-title":"Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine\/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis","volume":"25","author":"Jain T","year":"2019","unstructured":"Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine\/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019;25(4):728\u2013733.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41409-018-0226-1","article-title":"Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis","volume":"54","author":"Jain T","year":"2019","unstructured":"Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF, Sproat LZ, Fauble V, Mesa RA, Palmer J. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2019;54(2):204\u2013211.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan D","year":"2019","unstructured":"McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socie G, Bornhauser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itala-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poire X, Klyuchnikov E, Hernandez-Boluda JC, Czerw T, Hayden P, Kroger N, Yakoub-Agha I. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25(11):2167\u20132171.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"ref41","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","article-title":"Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis","volume":"22","author":"Robin M","year":"2016","unstructured":"Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuk F, Socie G, Kroger N. Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. Biol Blood Marrow Transplant. 2016;22(7):1206\u20131211.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron E","year":"2015","unstructured":"Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5(7):e333.","journal-title":"Blood Cancer J"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents","volume":"31","author":"Duchmann M","year":"2018","unstructured":"Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Ades L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine. 2018;31:174\u2013181.","journal-title":"EBioMedicine"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/bloodadvances.2020003600","article-title":"A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation","volume":"5","author":"Gagelmann N","year":"2021","unstructured":"Gagelmann N, Badbaran A, Beelen DW, Salit RB, Stolzel F, Rautenberg C, Becker H, Radujkovic A, Panagiota V, Bogdanov R, Christopeit M, Park Y, Nibourel O, Luft T, Koldehoff M, Corsten M, Heuser M, Finke J, Kobbe G, Platzbecker U, Robin M, Scott BL, Kroger N. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv. 2021;5(6):1760\u20131769.","journal-title":"Blood Adv"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2691216\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2691216\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T19:40:18Z","timestamp":1729107618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2691216\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":44,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2691216\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,3,21]]},"subtype":"preprint"}}